| Literature DB >> 35992792 |
Siyue Yin1,2, Yanxun Han2,3, Yuchen Liu2,3, Bangjie Chen1,2, Ziyue Fu2, Shuyan Sheng2, Jianpeng Wang2, Chuanlu Shen2, Xinyi Wang2, Yiwen Jia4.
Abstract
Background: This network meta-analysis aimed to comprehensively compare the operative and postoperative outcomes of different parotidectomy incisions.Entities:
Keywords: Bayesian network meta-analysis; V-shaped incision; modified Blair incision; modified facelift incision; parotidectomy; retroauricular hairline incision; surgical incision
Year: 2022 PMID: 35992792 PMCID: PMC9389557 DOI: 10.3389/fonc.2022.972498
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Parotidectomy via four incisions: (A) modified Blair incision, (B) modified facelift incision, (C) retroauricular hairline incision, (D) V-shaped incision.
Figure 2The Preferred Reporting Items for Systematic Reviews and network meta-analyses checklist (PRISMA-NMA) diagram.
Characteristics and NOS quality assessment of the included studies.
| Author, year, country | Study design | Surgical procedure | No. of patient | Age (years) | Gender (M/F) | Follow-up (months) | Tumor size (mm) | Newcastle-Ottawa Scale | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Selection | Comparability | Outcome | Total (9☆) | ||||||||
| Terris ( | RCS | MBI | 15 | 40.3 ± 24.6 | 5/10 | 7.7 ± nr | nr | ☆☆☆ | ☆ | ☆☆ | 6 |
| MFI | 17 | 40.3 ± 12.3 | 1/16 | 8.1 ± nr | |||||||
| Roh ( | RCS | MBI | 49 | 50.5 ± 15.7 | 23/26 | 48 ± 23 | 29 ± 19 | ☆☆☆☆ | ☆☆ | ☆☆☆ | 9 |
| MFI | 52 | 48.4 ± 14.6 | 24/28 | 47 ± 22 | 27 ± 18 | ||||||
| Wasson ( | RCS | MBI | 59 | 51 ± nr | 29/30 | ≥6 | nr | ☆☆☆☆ | ☆ | ☆ | 6 |
| MFI | 20 | 44 ± nr | 11/9 | ||||||||
| Bianchi ( | RCS | MBI | 35 | nr | nr | ≥18 | nr | ☆☆☆ | ☆ | ☆☆☆ | 7 |
| MFI | 48 | ||||||||||
| Lee ( | RCS | MBI | 162 | 45.82 ± 18.44 | 90/72 | 8.98 ± nr | 26.49 ± 11.94 | ☆☆☆☆ | ☆ | ☆☆ | 7 |
| MFI | 182 | 44.12 ± 16.76 | 51/131 | 23.76 ± 9.98 | |||||||
| Zhi ( | RCS | MBI | 20 | 49 ± nr | nr | 36 ± 0 | nr | ☆☆☆ | ☆ | ☆☆☆ | 7 |
| MFI | 18 | 45 ± nr | |||||||||
| Graciano ( | RCS | MBI | 30 | 47.3 ± nr | 21/9 | nr | 48.12 ± nr | ☆☆☆ | ☆ | ☆☆ | 6 |
| MFI | 30 | 34.93 ± nr | 11/19 | 34.29 ± nr | |||||||
| Kim ( | RCS | MBI | 16 | 45 ± nr | 6/10 | 29 ± NA | 27.1 ± nr | ☆☆☆ | ☆☆ | ☆☆☆ | 8 |
| MFI | 24 | 51 ± nr | 9/15 | 27.4 ± nr | |||||||
| RAHI | 33 | 46 ± nr | 14/19 | 27.8 ± nr | |||||||
| Bulut ( | RCS | MBI | 24 | 43 ± nr | 5/19 | 97 ± NA | 31 ± nr | ☆☆☆☆ | ☆ | ☆☆☆ | 8 |
| MFI | 24 | 43 ± nr | 5/19 | 29 ± nr | |||||||
| Wu ( | RCS | MBI | 28 | 47.2 ± 14.1 | 14/14 | 25 ± 0 | 22 ± 9 | ☆☆☆ | ☆☆ | ☆☆ | 7 |
| RAHI | 36 | 48.1 ± 18.0 | 22/14 | 24 ± 9 | |||||||
| Xu ( | PCS | MBI | 35 | 41.66 ± 13.18 | 17/18 | 48 ± nr | 37.2 ± 6.9 | ☆☆☆ | ☆ | ☆☆☆ | 7 |
| MFI | 36 | 39.46 ± 11.18 | 14/22 | 35.7 ± 6.5 | |||||||
| Zheng ( | PCS | MBI | 23 | 37.5 ± 8.9 | 11/12 | 19.2 ± 2.8 | 25.1 ± 5 | ☆☆☆ | ☆ | ☆☆ | 6 |
| VI | 23 | 36.2 ± 8.7 | 10/13 | 18.7 ± 2.6 | 23 ± 6 | ||||||
| Jo, Korea | PCS | MBI | 40 | 51.1 ± 17 | 19/21 | nr | 24.7 ± 7.9 | ☆☆☆☆ | ☆ | ☆ | 6 |
| VI | 34 | 46.3 ± 13.4 | 13/21 | 21.4 ± 5.8 | |||||||
| Ahn ( | RCS | MFI | 122 | 53.5 ± 14.8 | 71/51 | nr | 28 ± 11 | ☆☆☆☆ | ☆ | ☆☆ | 7 |
| RAHI | 50 | 51.8 ± 17.7 | 24/26 | 27 ± 10 | |||||||
| VI | 41 | 42.1 ± 14.5 | 12/29 | 19 ± 5 | |||||||
| Li ( | RCT | MBI | 20 | 43.35 ± 8.83 | 15/5 | nr | 22.5 ± nr | – | – | – | – |
| MFI | 20 | 45.95 ± 8.16 | 16/4 | 17 ± nr | |||||||
| VI | 20 | 43.40 ± 9.89 | 16/4 | 18 ± nr | |||||||
| Zhang, China | RCS | MBI | 36 | nr | 23/13 | 6 | nr | ☆☆☆ | ☆☆ | ☆ | 6 |
| MFI | 32 | nr | |||||||||
| Chen ( | RCS | MFI | 29 | 56 ± 11.86 | 16/13 | nr | 27.7 ± 9.9 | ☆☆☆ | ☆ | ☆☆ | 6 |
| RAHI | 19 | 39 ± 14.49 | 6/13 | 24.3 ± 9 | |||||||
| Matsumoto ( | RCS | MBI | 97 | 50.71 ± 15.08 | 35/62 | nr | 26.36 ± 10.77 | ☆☆☆ | ☆☆ | ☆☆ | 7 |
| MFI | 78 | 51.99 ± 13.53 | 29/49 | nr | 25.78 ± 11.85 | ||||||
RCS, retrospective cohort study; PCS, prospective cohort study; RCT, randomized controlled trial; MBI, modified Blair incision; MFI, modified facelift incision; RAHI, retroauricular hairline incision; VI, V-shaped incision; nr, not reported. The number of * corresponds to the score.
Risk of bias assessment in cohort studies by ROBINS-I.
| Study | Year | Bias due to confounding | Bias in selection of participants into the study | Bias in classification of interventions | Bias due to deviations from intendedinterventions | Bias due to missing data | Bias in measurement of outcomes | Bias in selection of the reported result | Overall |
|---|---|---|---|---|---|---|---|---|---|
| Terris |
| Moderate | Moderate | Low | Low | Low | Moderate | Low | Moderate |
| Roh |
| Low | Low | Low | Low | Low | Low | Low | Low |
| Wasson |
| Critical | Low | Low | Low | Low | Low | Low | Critical |
| Bianchi |
| Low | Moderate | Low | Low | Moderate | Low | Low | Moderate |
| Lee |
| Low | Low | Low | Low | Low | Low | Low | Low |
| Zhi |
| Low | Low | Low | Low | Low | Low | Low | Low |
| Graciano |
| Moderate | Moderate | Low | Low | Low | Low | Low | Moderate |
| Kim |
| Low | Low | Low | Low | Low | Low | Low | Low |
| Bulut |
| Low | Low | Low | Low | Moderate | Low | Low | Moderate |
| Wu |
| Low | Low | Low | Low | Low | Low | Low | Low |
| Xu |
| Low | Low | Low | Low | Low | Low | Low | Low |
| Zheng |
| Moderate | Moderate | Low | Low | Low | Low | Low | Moderate |
| Jo | Low | Low | Low | Low | Low | Low | Low | Low | |
| Zhang | Critical | Moderate | Low | Low | Low | Low | Low | Critical | |
| Ahn |
| Moderate | Low | Low | Low | Low | Low | Low | Moderate |
| Chen |
| Low | Moderate | Low | Low | Low | Low | Low | Moderate |
| Matsumoto |
| Low | Low | Low | Low | Low | Low | Low | Low |
Risk of bias of one RCT with Cochrane Collaboration tools.
| Risk of bias | Li et al., 2020, China |
|---|---|
| Random sequence generation | Quote: “Patients meeting the inclusion criteria were randomly divided into three incision groups by lottery” |
| Allocation concealment | Impossible due to nature of surgery and |
| Blinding of participants and personnel | Impossible due to nature of surgery and |
| Blinding of outcome assessme | Impossible due to nature of surgery and |
| Incomplete outcome data | There was no incomplete or missing data. |
| Selective reporting | Consistency between outcome measure in |
| Other bias | There were no other sources of bias |
Red, yellow and green correspond to a high risk, unknown risk and low risk of bias, respectively.
Figure 3A direct comparison forest map of continuous outcomes.
Figure 4A direct comparison forest map of dichotomous outcomes.
Figure 5Network maps of all outcomes: (A) incision satisfaction score, (B) operation time, (C) drainage volume, (D) tumor size, (E) hematoma, (F) wound infection, (G) permanent facial palsy, (H) transient facial palsy, (I) salivary complications, (J) Frey syndrome.
League table of primary outcomes.
| MBI | A | |||
|---|---|---|---|---|
| -0.76 (-2.19,0.66) |
| |||
| -1.95 (-4.08,0.17) | -1.18 (-3.30,0.93) |
| ||
| -2.47 (-4.51,-0.43) | -1.70 (-4.04,0.62) | -0.52 (-3.39,2.35) |
| |
|
| B | |||
| -1.67 (-11.49,10.39) |
| |||
| -0.40 (-13.52,14.08) | 1.30 (-12.60,14.16) |
| ||
| -3.53 (-17.91,9.81) | -1.86 (-18.42,11.48) | -3.12 (-21.20,12.57) |
| |
|
| C | |||
| -3.22 (-15.16,5.55) |
| |||
| 7.54 (-13.56,22.30) | 10.99 (-6.35,24.47) |
| ||
| 0.36 (-10.68,11.63) | 3.67 (-7.12,17.53) | -7.15 (-22.19,14.14) |
| |
|
| D | |||
| 1.04 (0.30,7.49) |
| |||
| 0.56 (0.11,25.13) | 0.37 (0.07,18.85) |
| ||
| 0.60 (0.13,11.98) | 0.36 (0.07.10.17) | 0.15 (0.03,20.62) |
|
Values of A, B, and C are expressed as mean difference (MD) and 95% credible intervals (95% CrI).
Values of D is expressed as odds ratio (OR) and 95% credible intervals (95% CrI).
A incision satisfaction score, B operation time, C drainage volume, D permanent facial palsy.
The bold values indicate that the comparison between the two is statistically significant.
League table of secondary outcomes.
| MBI | Tumor size | |||
|---|---|---|---|---|
| -0.01(-3.44,3.39) |
| |||
| -0.26 (-5.04,4.71) | -0.24(-4.90,4.61) |
| ||
|
|
| 5.41(-0.28,10.73) |
| |
|
|
| |||
| 1.22(0.35,9.09) |
| |||
| 0.52(0.10,33.33) | 0.28(0.05,16.67) |
| ||
| 0.33(0.07,12.50) | 0.15(0.03,9.09) | 0.08(0.02,16.67) |
| |
|
|
| |||
| 0.84(0.21,10.13) |
| |||
| 0.26(0.07,98.14) | 0.10(0.04,80.26) |
| ||
| 0.12(0.09,17,69) | 0.03(0.04,22.54) | 0.001(0.01,49.00) |
| |
|
|
| |||
|
|
| |||
| 1.37(0.60,4.00) | 0.69(0.30,1.96) |
| ||
| 1.23(0.50,4.17) | 0.62(0.25,2.13) | 0.75(0.26,3.45) |
| |
|
|
| |||
| 1.36(0.73,2.83) |
| |||
| 1.60(0.59,6.56) | 1.11(0.42,4.62) |
| ||
| 0.86(0.37,2.57) | 0.59(0.25,1.85) | 0.39(0.12,1.99) |
| |
|
|
| |||
| 1.41(0.77,2.63) |
| |||
| 1.57(0.66,5.17) | 1.06(0.45,3.55) |
| ||
| 3.11(0.80,62.03) | 2.08(0.53,42.44) | 1.57(0.37,38.00) |
|
The bold values indicate that the comparison between the two is statistically significant.
SUCRA of secondary outcomes.
| Outcomes (%)Incisions | MBI | MFI | RAHI | VI |
|---|---|---|---|---|
| tumor size | 36 | 35 | 31 | 98 |
| hematoma | 40 | 67 | 56 | 37 |
| wound infection | 37 | 54 | 60 | 49 |
| transient facial palsy | 15 | 82 | 55 | 49 |
| salivary complications | 26 | 66 | 79 | 28 |
| Frey syndrome | 9 | 46 | 57 | 89 |
The smaller the tumor size, the greater the SUCRA value.
The lower the incidence of adverse outcomes, the higher the SUCRA value.
Quality of evidence for outcomes based on the GRADE method.
| Outcomes | Comparison | Study limitations | Imprecision | Inconsistency | Indirectness | Quality of evidence |
|---|---|---|---|---|---|---|
| incision satisfaction score | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | No downgraded | No downgraded | No downgraded | Low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | Downgraded | Very low | |
| operation time | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| drainage volume | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | Downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| permanent facial nerve palsy | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| tumor size | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | No downgraded | No downgraded | No downgraded | Low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | No downgraded | No downgraded | No downgraded | Low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| hematoma | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| wound infection | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | Downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | Downgraded | Very low | |
| transient facial palsy | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| salivary complications | MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
|
| MBI vs. MFI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
| MBI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MBI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. RAHI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| MFI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low | |
| RAHI vs. VI | Downgraded | Downgraded | No downgraded | No downgraded | Very low |
Based on all the above information, we GRADEd each network estimate according to the following criteria.
(1) Study limitations: We downgraded by evidence at high risk of bias.
(2) Imprecision: We considered a clinically meaningful threshold for OR to be 0.80 or 1.25 and downgraded the estimate if the OR point estimate is 1 or more and the lower limit of its CrI is below 0.80; or if the OR point estimate is less than 1 and the upper limit of its CrI is above 1.25. We downgraded when the CrI of MD included zero between the upper and lower CrI limits.
(3) Inconsistency: We looked at the results of node-splitting and we downgraded the comparisons with important inconsistency (p<0.05), where we have not downgraded for imprecision.
(4) Indirectness: We downgraded singly-connected nodes for indirectness because evaluation of transitivity for such nodes is unclear.
(5) Publication bias: Publication bias could not be assessed as there were <10 trials available for each of the comparisons.